Improving tuberculosis management in prisons: Impact of a rapid molecular point-of-care test - 17/02/21
Highlights |
• | Molecular point-of-care test can improve tuberculosis management in prison. |
• | Xpert MTB/RIF Ultra performs similarly on raw and decontaminated sputa. |
• | Xpert MTB/RIF Ultra can be implemented in a prison structure. |
• | Systematic Xpert MTB/RIF Ultra of inmates accelerates tuberculosis diagnosis. |
Summary |
Objective |
To improve tuberculosis (TB) diagnosis in prison, we evaluate the value of the XpertⓇMTB/RIF Ultra assay (Xpert) as point-of-care (POC) in a French prison hospital.
Methods |
We first validated Xpert use on raw sputum at the referent laboratory. Secondly, trained physicians at the prison hospital performed Xpert tests for each patient presenting TB symptoms. The results were compared with Xpert, microscopic examination, culture and drug susceptibility testing on the corresponding decontaminated specimens.
Results |
76 inmates were included in 15 months and 21 were diagnosed with TB. The overall sensitivity, specificity, positive and negative predictive values of Xpert were respectively: 92.3%, 100%, 100% and 98.7% on raw sputum. The efficiency of the molecular POC was confirmed by a concordance of 97% between Xpert findings from the prison hospital and culture results. Delay of microbiological diagnosis was reduced by about 18 days for 13 inmates with smear-negative sputum that avoid the mobilization of major means (escort, transport) to perform fibroscopic samples. Repeated Xpert negative results helped to speed the lifting of inmate isolation.
Conclusions |
The implementation of Xpert in prison could optimize the management of incarcerated patients and thus limit the spread of TB among inmates, carers and other staff.
Le texte complet de cet article est disponible en PDF.Keywords : Tuberculosis, Prison, XpertⓇMTB/RIF Ultra, Molecular diagnosis, Screening
Plan
Vol 82 - N° 2
P. 235-239 - février 2021 Retour au numéro
Article précédent
- Risk factors and outcomes associated with the carriage of tigecycline- and vancomycin-resistant Enterococcus faecium
- Johanna Kessel, Jennifer Bender, Guido Werner, Matas Griskaitis, Eva Herrmann, Annette Lehn, Hubert Serve, Kai Zacharowski, Stefan Zeuzem, Maria J.G.T. Vehreschild, Thomas A. Wichelhaus, Volkhard A.J. Kempf, Michael Hogardt
- Predicting drug-induced liver injury from anti-tuberculous medications by early monitoring of liver tests
- Benjamin Patterson, Aula Abbara, Simon Collin, Merle Henderson, Monicka Shehata, Hannah Gorgui-Naguib, William Lynn, Onn Min Kon, Laurence John
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?